The National Institute for Health and Clinical Excellence has published guideline on the use of antibiotics for respiratory tract infections recommending that alternative prescription strategies are used for patients with RTIs who present in primary care and other first face-to-face contact health care settings such as emergency departments and walk-in centers in England, Wales and Northern Ireland.
The government agent that advises the UK's National Health Service on the use of drugs and other treatments suggests that no antibiotics should be prescribed at first, with one written for use at a later date should symptoms worsen, as well as immediate antibiotic prescribing. Evidence shows that antibiotics have limited effectiveness in treating a large proportion of RTIs and complications are likely to be rare if antibiotics are withheld, the NICE said. Consultation rates in England and Wales show that a quarter of the population will visit their general practicioner because of an RTI each year and they are the reason for 60% of all antibiotic prescribing in this setting.
Key recommendations to doctors in the guidelines are: "negotiate a no antibiotic or delayed antibiotic prescribing strategy for patients with acute otitis media, acute sore throat/pharyngitis/acute tonsillitis, common cold, acute rhinosinusitis or acute cough/acute bronchitis." The NICE tells GPs to reassure patients that antibiotics are not needed immediately because they will make little difference to symptoms and may have side effects, and to do a clinical review if the RTI worsens or becomes prolonged.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze